Suggested remit - To appraise the clinical and cost effectiveness of siponimod within its marketing authorisation for treating secondary progressive multiple sclerosis in adults
 
Status In progress
Process STA 2018
ID number 1304

Provisional Schedule

Committee meeting: 1 12 March 2020
Expected publication 03 June 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Novartis (siponimod)
Others Department of Health and Social Care
  NHS England
  NHS Great Yarmouth & Waveney CCG
  NHS Islington CCG
  Welsh Government
Patient carer groups The Brain Charity
  Brain and Spine Foundation -
  Disability Rights UK
  Leonard Cheshire Disability
  MS-UK
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Muslim Council of Britain
  Neurological Alliance
  Shift.ms
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  British Association of Neuroscience Nurses
  British Geriatrics Society
  British Neuropathological Society
  British Society for Blood and Marrow Transplantation
  British Society of Rehabilitation Medicine
  Chartered Society of Physiotherapy
  Institute of Neurology
  London MS-AHSCT Collaborative Group
  Primary Care Neurology Society
  Therapists in MS
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Occupational Therapists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Multiple Sclerosis Specialist Nurse Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Novartis (interferon beta 1b)
  Bayer (interferon beta 1b)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research Trust
  British Neurological Research Trust
  Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  Genomics England
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
16 July 2019 Invitation to participate
16 July 2019 In progress, Appraisal has been referred to NICE.
20 November 2018 - 18 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance